Online inquiry

IVTScrip™ mRNA-Anti-FGFR4, M-70(Cap 1, 2-Thio-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ10778MR)

This product GTTS-WQ10778MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & 2-Thio-UTP. It ecodes the monoclonal antibody that targets FGFR4 gene. The antibody can be applied in Non-alcoholic steatohepatitis (NASH) research.
Specifications
Product type mRNA
Modified bases 2-Thio-UTP
5' Cap Cap 1
Species Homo sapiens
RefSeq NM_001291980.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 2264
UniProt ID P22455
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-FGFR4, M-70(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) (GTTS-WQ10778MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ5822MR IVTScrip™ mRNA-Anti-CD3E, ChAglyCD(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA ChAglyCD
GTTS-WQ12134MR IVTScrip™ mRNA-Anti-CD248, MORAb-004(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA MORAb-004
GTTS-WQ12494MR IVTScrip™ mRNA-Anti-MUC5AC, NOE-102(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA NOE-102
GTTS-WQ13283MR IVTScrip™ mRNA-Anti-PTK7, PF-06523435(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA PF-06523435
GTTS-WQ5737MR IVTScrip™ mRNA-Anti-CEACAM5, CEA-IL-2v(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA CEA-IL-2v
GTTS-WQ5170MR IVTScrip™ mRNA-Anti-Canlupfam IL31, CAN34D3-65(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA CAN34D3-65
GTTS-WQ4610MR IVTScrip™ mRNA-Anti-KIR2DL1&KIR2DL2&KIR2DL3&KIR2DS1&KIR2DS2, BMS-986015(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA BMS-986015
GTTS-WQ13639MR IVTScrip™ mRNA-Anti-TNFSF4, R4930(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA R4930
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW